DUSP6 and neoplasm: We measured the response of tumour cells to treatment with a single dose of 10, 25 or 50 mg kg−1 RMC-7977 using quantitative PCR with reverse transcription (RT–qPCR) for human DUSP6, a RAS–MAPK pathway transcriptional target.